Skip to main content

Brant Allen Inman, MD, MS

Professor of Surgery
Office: 3007 Snyderman Bldg, 905 La Salle Street, Durham, NC 27710
Campus Mail: DUMC DUMC Box 103868, Durham, NC 27710

Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.

Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers

Education and Training

  • Fellowship, Urologic Oncology, Mayo Clinic, 2005 - 2008
  • Residency, Urology, Universite Laval (Canada), 2001 - 2005
  • M.S., Mayo Clinic, Alix School of Medicine, 2011
  • M.D., University of Alberta (Canada), 2000
  • B.S., University of Alberta (Canada), 1999

Selected Grants


Rigiroli, Francesca, Dylan Zhang, Jeroen Molinger, Yingqi Wang, Andrew Chang, Paul E. Wischmeyer, Brant A. Inman, and Rajan T. Gupta. “Automated versus manual analysis of body composition measures on computed tomography in patients with bladder cancer.” Eur J Radiol 154 (June 16, 2022): 110413.

Full Text

Cheng, Qing, William Butler, Yinglu Zhou, Hong Zhang, Lu Tang, Kathryn Perkinson, Xufeng Chen, et al. “Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.” Eur Urol 81, no. 5 (May 2022): 446–55.

Full Text

Guerrero-Ramos, Félix, Daniel A. González-Padilla, Alejandro González-Díaz, Federico de la Rosa-Kehrmann, Alfredo Rodríguez-Antolín, Brant A. Inman, and Felipe Villacampa-Aubá. “Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.” World J Urol 40, no. 4 (April 2022): 999–1004.

Full Text

Mitra, Anirban P., Vikram M. Narayan, Sharada Mokkapati, Tanner Miest, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, et al. “Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.” Eur Urol 81, no. 3 (March 2022): 223–28.

Full Text

Kibel, Adam S., Brant A. Inman, Russell K. Pachynski, Tuyen Vu, Nadeem A. Sheikh, and Daniel P. Petrylak. “Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.” J Natl Cancer Inst 114, no. 2 (February 7, 2022): 310–13.

Full Text

Berger, Miles, Jeffrey N. Browndyke, Mary Cooter Wright, Chloe Nobuhara, Melody Reese, Leah Acker, W Michael Bullock, et al. “Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers.” Ann Clin Transl Neurol 9, no. 2 (February 2022): 155–70.

Full Text

Browndyke, Jeffrey N., Mary C. Wright, Rosa Yang, Ayesha Syed, John Park, Ashley Hall, Katherine Martucci, et al. “Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort study.” Br J Anaesth 127, no. 6 (December 2021): 917–28.

Full Text

Harrison, M. R., B. A. Costello, N. A. Bhavsar, U. Vaishampayan, S. K. Pal, Y. Zakharia, H. S. L. Jim, et al. “Re: Active Surveillance of Metastatic Renal Cell Carcinoma: Results from a Prospective Observational Study (MaRCC).” Journal of Urology 206, no. 6 (December 2021): 1515–16.